This result is consistent with the observation that by inhibiting autophagy and reversing the reduced sensitivity of tamoxifen caused by the downregulation of MED16, we propose that autophagy inhibitors, in combination with tamoxifen, may lead to a better prognosis for patients with ER+ breast cancer. Here, ESR1 is linked to breast carcinoma.